Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;11(1):101-7.
doi: 10.4161/hv.34363. Epub 2014 Nov 1.

Reducing the burden of Herpes Zoster in Italy

Giovanni Gabutti  1 , Elisabetta Franco, Paolo Bonanni, Michele Conversano, Antonio Ferro, Marzia Lazzari, Stefania Maggi, Alessandro Rossi, Silvestro Scotti, Francesco Vitale, Antonio Volpi, Donato Greco
Affiliations
Review

Reducing the burden of Herpes Zoster in Italy

Giovanni Gabutti et al. Hum Vaccin Immunother. 2015.

Abstract

Herpes Zoster (HZ) is a viral disease with painful neuro-dermatologic manifestations. Incidence increases with age. In Italy, the estimated incidence is 6.3 cases/1000 person/year; hospital admissions are less than 2%, 69% in patients aged over 65 years. The most frequent complication of HZ is Post-Herpetic Neuralgia (PHN) characterized by metameric pain, allodynia, and hyperalgesia. In Italy 20.6% and 9.2% of HZ patients experience PHN after 3 and 6 months, respectively. Available antiviral and analgesic treatments are relatively unsatisfactory in reducing pain and length of the disease. Prevention has recently become possible with the live attenuated vaccine Oka/Merck. Clinical studies show a reduction of 51% in the incidence of the disease, 61% of its burden and 67% of PHN in vaccinees. Protection seems to be long lasting and vaccine safety matches registration requirements. Available evidence suggests that the costs for QALY (less than € 20 000) and avoided cases is favorable. Due to the heavy burden of disease, it is time to offer this vaccination to elderly population.

Keywords: Herpes Zoster; burden; epidemiology; immunization; prevention.

PubMed Disclaimer

References

    1. Marin M, Güris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC).. Prevention of varicella. Recommendations of the Advisory Committee on immunization practices (ACIP). MMWR Recomm Rep 2007; 56:RR-4 1 - 40; PMID: 17585291 - PubMed
    1. Grose C.. Varicella vaccination of children in the United States: assessment after the first decade 1995-2005. J Clin Virol 2005; 33:89 - 95, discussion 96-8; http://dx.doi.org/10.1016/j.jcv.2005.02.003; PMID: 15911422 - DOI - PubMed
    1. Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC).. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:RR-5 1 - 30, quiz CE2-4; PMID: 18528318 - PubMed
    1. Kimberlin DW, Whitley RJ.. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; 356:1338 - 43; http://dx.doi.org/10.1056/NEJMct066061; PMID: 17392303 - DOI - PubMed
    1. Johnson RW, Wasner G, Saddier P, Baron R.. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008; 25:991 - 1006; http://dx.doi.org/10.2165/0002512-200825120-00002; PMID: 19021299 - DOI - PubMed

MeSH terms

Substances